Curevac announces financial results for the third quarter and first nine months of 2022 and provides business update
Delivering on broad second-generation vaccine development program with expansion into modified mrna technology in collaboration with gsk phase 1 studies in influenza and covid-19 on track to deliver clinical data in q1 2023 strengthening oncology position based on preparations for new clinical studies with mrna-based cancer vaccine candidates and positive phase 1 data on cv8102 two proof-of-principle studies planned in 2023 to validate and optimize second-generation mrna backbone in oncology phase 1 expansion study of non-coding rna-based candidate cv8102 confirms safety and strong immuno-modulatory characteristics first manufacturing licenses for the rna printer® in oncology expected, subject to regulatory approval; applications submitted to regulatory authorities in q4 2022 driving innovation at the 10 th international mrna health conference with data on novel lnp delivery system and therapeutic approaches for diseases with high unmet medical need cash and cash equivalents position of €540.9 million as of september 30, 2022; driven mainly by proceeds related to transfer of production capacity to gsk tÜbingen, germany and boston, ma / accesswire / november 16, 2022 / curevac n.v. (nasdaq:cvac), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced financial results for the third quarter and first nine months of 2022 and provided a business update.
CVAC Ratings Summary
CVAC Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission